These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 25481044

  • 1. Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells.
    Jaganathan S, Malek E, Vallabhapurapu S, Vallabhapurapu S, Driscoll JJ.
    Oncotarget; 2014 Dec 15; 5(23):12358-70. PubMed ID: 25481044
    [Abstract] [Full Text] [Related]

  • 2. Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells.
    Min H, Xu M, Chen ZR, Zhou JD, Huang M, Zheng K, Zou XP.
    Cancer Chemother Pharmacol; 2014 Jul 15; 74(1):167-76. PubMed ID: 24842158
    [Abstract] [Full Text] [Related]

  • 3. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 4. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis.
    Yousefi S, Perozzo R, Schmid I, Ziemiecki A, Schaffner T, Scapozza L, Brunner T, Simon HU.
    Nat Cell Biol; 2006 Oct 01; 8(10):1124-32. PubMed ID: 16998475
    [Abstract] [Full Text] [Related]

  • 5. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
    Balsas P, Galán-Malo P, Marzo I, Naval J.
    Leuk Res; 2012 Feb 01; 36(2):212-8. PubMed ID: 21978467
    [Abstract] [Full Text] [Related]

  • 6. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress.
    Kawaguchi T, Miyazawa K, Moriya S, Ohtomo T, Che XF, Naito M, Itoh M, Tomoda A.
    Int J Oncol; 2011 Mar 01; 38(3):643-54. PubMed ID: 21174067
    [Abstract] [Full Text] [Related]

  • 7. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D, Mitsiades N, Richardson P, Chang Y, Schindler J, Carver B, Anderson KC.
    Cancer Res; 2005 Sep 15; 65(18):8350-8. PubMed ID: 16166312
    [Abstract] [Full Text] [Related]

  • 8. Role of AMP-activated protein kinase in cross-talk between apoptosis and autophagy in human colon cancer.
    Song X, Kim SY, Zhang L, Tang D, Bartlett DL, Kwon YT, Lee YJ.
    Cell Death Dis; 2014 Oct 30; 5(10):e1504. PubMed ID: 25356873
    [Abstract] [Full Text] [Related]

  • 9. Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells.
    Song IS, Kim HK, Lee SR, Jeong SH, Kim N, Ko KS, Rhee BD, Han J.
    Int J Cancer; 2013 Sep 15; 133(6):1357-67. PubMed ID: 23463417
    [Abstract] [Full Text] [Related]

  • 10. MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
    Jagannathan S, Vad N, Vallabhapurapu S, Vallabhapurapu S, Anderson KC, Driscoll JJ.
    Leukemia; 2015 Mar 15; 29(3):727-38. PubMed ID: 25234165
    [Abstract] [Full Text] [Related]

  • 11. Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro.
    Lou Z, Ren T, Peng X, Sun Y, Jiao G, Lu Q, Zhang S, Lu X, Guo W.
    J Int Med Res; 2013 Oct 15; 41(5):1505-19. PubMed ID: 23975859
    [Abstract] [Full Text] [Related]

  • 12. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
    Que W, Chen J, Chuang M, Jiang D.
    APMIS; 2012 Mar 15; 120(3):195-203. PubMed ID: 22339676
    [Abstract] [Full Text] [Related]

  • 13. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
    de Wilt LH, Jansen G, Assaraf YG, van Meerloo J, Cloos J, Schimmer AD, Chan ET, Kirk CJ, Peters GJ, Kruyt FA.
    Biochem Pharmacol; 2012 Jan 15; 83(2):207-17. PubMed ID: 22027222
    [Abstract] [Full Text] [Related]

  • 14. Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo.
    Escalante AM, McGrath RT, Karolak MR, Dorr RT, Lynch RM, Landowski TH.
    Cancer Chemother Pharmacol; 2013 Jun 15; 71(6):1567-76. PubMed ID: 23572175
    [Abstract] [Full Text] [Related]

  • 15. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
    Balsas P, López-Royuela N, Galán-Malo P, Anel A, Marzo I, Naval J.
    Biochem Pharmacol; 2009 Mar 01; 77(5):804-12. PubMed ID: 19100720
    [Abstract] [Full Text] [Related]

  • 16. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, Bataille R, Amiot M.
    Cancer Res; 2007 Jun 01; 67(11):5418-24. PubMed ID: 17545623
    [Abstract] [Full Text] [Related]

  • 17. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M, Tabayashi T, Kimura Y, Tomikawa T, Nemoto-Anan T, Watanabe R, Tokuhira M, Ri M, Hashimoto Y, Iida S, Kizaki M.
    Cancer Sci; 2015 Apr 01; 106(4):438-46. PubMed ID: 25613668
    [Abstract] [Full Text] [Related]

  • 18. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.
    J Natl Cancer Inst; 2010 Jul 21; 102(14):1069-82. PubMed ID: 20505154
    [Abstract] [Full Text] [Related]

  • 19. Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells.
    Ju D, Xie Y.
    Mol Med Rep; 2014 Nov 21; 10(5):2609-12. PubMed ID: 25174315
    [Abstract] [Full Text] [Related]

  • 20. Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib.
    Jagannathan S, Abdel-Malek MA, Malek E, Vad N, Latif T, Anderson KC, Driscoll JJ.
    Leukemia; 2015 Nov 21; 29(11):2184-91. PubMed ID: 26108695
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.